Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here’s a rundown of the report.
Total revenue was up 7.7% on a year-over-year basis. New business awards totaled $529.7 million in the quarter, down 13.8% year-over-year. The company ended the period with a backlog of approximately $2.9 billion, up 3.2% year-over-year.
Medpace generated $190.7 million in cash flow from operations during the quarter. The company had cash and cash equivalents of $669.4 million as of Dec. 31.
Medpace said it repurchased $174.2 million of its common stock during the quarter. The company had $134.6 million remaining under its buyback at quarter’s end. Additionally, Medpace’s board approved an increase of $600 million to the company’s buyback program on Feb. 6.
Check This Out: Lattice Semiconductor Shares Jump After Mixed Q4 Results, Strong Q1 Guidance
Outlook: Medpace expects full-year 2025 revenue to be in the range of $2.11 billion to $2.21 billion. The company sees full-year earnings in the range of $11.93 per share to $12.69 per share.
Medpace executives will further discuss the quarter on a call with investors and analysts at 9 a.m. ET Tuesday morning.
MEDP Price Action: At publication time Monday, Medpace shares were down 8.33% at $324.97 in after-hours trading, according to Benzinga Pro.
Photo: Shutterstock.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。